Method of detecting pancreatic cancer
AssigneeJ-Oil Mills, Inc.
InventorsYuka Kobayashi, Ken Kusama, Masugu Kamei
Life of this patent
Estimating the term…
Abstract
To provide a method of accurately detecting pathological haptoglobin using a lectin having strong affinity and high specificity for fucose. The method of the present invention for detecting pancreatic cancer is characterized in that a fucose α1→6 specific lectin is allowed to act on pathological haptoglobin contained in a sample obtained from a living body, said lectin: (1) being extractede from basidiomycetes, (2) having a molecular weight of 4,000 to 40,000 as determined by the SDS polyacrylamide gel electrophoresis, and (3) having affinity for a fucose α1→6 sugar chain with a binding constant of 1.0×104 M−1 or more at 25° C.
Claims16
A method of detecting pancreatic cancer, comprising:
- collecting a sample from a living body of a suspected patient;
- contacting a fucose α1→6 specific lectin to the sample in order to be allowed to act on pathological haptoglobin present in the sample obtained from the living body and obtain a lectin-pathological haptoglobin complex, said lectin:
- (1) being extracted from basidiomycetes,
- (2) having a molecular weight of 4,000 to 40,000 as determined by the SDS polyacrylamide gel electrophoresis,
- (3) having affinity for fucose α1→6 sugar chains with a binding constant of 1.0×104 M−1 or more at 25° C., and
- (4) having a binding constant 1.0×103 M−1 or less at 25° C. for a high mannose sugar chain, which is an asparagine-linked sugar chain wherein a chitobiose core is bound to five to nine mannose residues, and/or a glycolipid which does not contain a fucose α1→6 sugar chain;
- and
- determining the lectin-pathological haptoglobin complex by an assay selected from the group consisting of ELISA, lectin chromatography, lectin blotting, lectin staining, lectin chip, a condensation method and a surface plasmon resonance method to detect the occurrence of the pancreatic cancer.
A method of detecting pancreatic cancer or pancreatitis, comprising:
- collecting a sample from a living body of a suspected patient having 30 U/mL or more of tumor marker CA 19-9 in serum;
- contacting a fucose α1→6 specific lectin to the sample in order to be allowed to act on pathological haptoglobin present in the sample obtained from the living body and obtain a lectin-pathological haptoglobin complex, said lectin:
- (1) being extracted from basidiomycetes,
- (2) having a molecular weight of 4,000 to 40,000 as determined by the SDS polyacrylamide gel electrophoresis,
- (3) having affinity for fucose α1→6 sugar chains with a binding constant of 1.0×104 M−1 or more at 25° C., and
- (4) having a binding constant of 1.0×103 M−1 or less at 25° C. for a high mannose sugar chain, which is an asparagine-linked sugar chain wherein a chitobiose core is bound to five to nine mannose residues, and/or a glycolipid which does not contain a fucose α1→6 sugar chain;
- and
- determining the lectin-pathological haptoglobin complex by an assay selected from the group consisting of ELISA, lectin chromatography, lectin blotting, lectin staining, lectin chip, a condensation method and a surface plasmon resonance method to detect the occurrence of the pancreatic cancer.
A diagnostic reagent or kit for detecting pancreatic cancer and/or pancreatitis, comprising:
- a fucose α1→6 specific lectin, said lectin:
- (1) being extracted from basidiomycetes,
- (2) having a molecular weight of 4,000 to 40,000 as determined by the SDS polyacrylamide gel electrophoresis,
- (3) having affinity for fucose α1→6 sugar chains with a binding constant of 1.0×104 M−1 or more at 25° C., and
- (4) having a binding constant of 1.0×103 M−1 or less at 25° C. for a high mannose sugar chain, which is an asparagine-linked sugar chain wherein a chitobiose core is bound to five to nine mannose residues, and/or a glycolipid which does not contain a fucose α1→6 sugar chain;
- and
- an anti-haptoglobin antibody.
Dependencies are inferred from the claim text.